Health Care Providers Have Knowledge Gap On Biosimilars, Accelerated Approval
Executive Summary
FDA’s 2019 survey of 2,000 providers finds 31% do not know what biosimilars are and 30% of primary care physicians do not know what an accelerated approval drug is. Another survey of low- or non-internet users finds a toll-free number is the best way for them to find information about a drug’s risks.
You may also be interested in...
TV Drug Advertising Study Targets Those With Limited Or No Internet Use
US FDA will assess value of including 1-800 number and print ad in broadcast commercials; it is among 42 direct-to-consumer studies the agency has undertaken, 13 of which are in progress.
FDA Urged To Collaborate With USPTO On Orange Book Listings, Eliminate Patent Use Codes
Stakeholders suggest a variety of USPTO and FDA actions that could help ensure patents do not improperly delay generic and biosimilar competition.
FDA Urged To Collaborate With USPTO On Orange Book Listings, Eliminate Patent Use Codes
Stakeholders suggest a variety of USPTO and FDA actions that could help ensure patents do not improperly delay generic and biosimilar competition.